| Primary |
| Glioblastoma Multiforme |
24.5% |
| Glioblastoma |
19.7% |
| Drug Use For Unknown Indication |
9.0% |
| Product Used For Unknown Indication |
7.4% |
| Anaplastic Astrocytoma |
7.1% |
| Prophylaxis |
6.0% |
| Oligodendroglioma |
3.5% |
| Glioma |
3.4% |
| Brain Neoplasm |
2.7% |
| Malignant Glioma |
2.7% |
| Astrocytoma |
2.2% |
| Antifungal Prophylaxis |
1.7% |
| Metastatic Malignant Melanoma |
1.7% |
| Epilepsy |
1.6% |
| Lymphoma |
1.5% |
| Metastases To Central Nervous System |
1.1% |
| Recurrent Cancer |
1.1% |
| Central Nervous System Lymphoma |
1.0% |
| Brain Oedema |
1.0% |
| Convulsion |
1.0% |
|
| Thrombocytopenia |
15.3% |
| White Blood Cell Count Decreased |
12.8% |
| Pneumonia |
8.5% |
| Vomiting |
7.1% |
| Pancytopenia |
6.3% |
| Pulmonary Embolism |
5.9% |
| Death |
5.8% |
| Sepsis |
5.2% |
| Pyrexia |
3.7% |
| Platelet Count Decreased |
3.5% |
| Urinary Tract Infection |
3.5% |
| Respiratory Failure |
3.3% |
| Tumour Haemorrhage |
3.2% |
| Hepatic Function Abnormal |
3.1% |
| Neoplasm Progression |
2.6% |
| Septic Shock |
2.6% |
| Pneumocystis Jiroveci Pneumonia |
2.5% |
| Disease Progression |
2.0% |
| Bone Marrow Failure |
1.8% |
| Febrile Bone Marrow Aplasia |
1.5% |
|
| Secondary |
| Prophylaxis |
37.6% |
| Product Used For Unknown Indication |
16.7% |
| Glioblastoma Multiforme |
9.0% |
| Anaplastic Astrocytoma |
6.1% |
| Antifungal Prophylaxis |
6.1% |
| Status Epilepticus |
3.6% |
| Epilepsy |
3.6% |
| Glioblastoma |
3.3% |
| Drug Use For Unknown Indication |
2.3% |
| Constipation |
1.8% |
| Brain Neoplasm |
1.3% |
| Convulsion |
1.3% |
| Hypertension |
1.1% |
| Dermatitis |
1.0% |
| Malignant Glioma |
1.0% |
| Nausea |
1.0% |
| Vomiting |
0.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.8% |
| Glioma |
0.7% |
| Intracranial Pressure Increased |
0.6% |
|
| White Blood Cell Count Decreased |
25.3% |
| Vomiting |
11.8% |
| Pyrexia |
9.5% |
| Convulsion |
7.0% |
| Multi-organ Failure |
7.0% |
| Cerebral Infarction |
5.6% |
| Pancytopenia |
3.7% |
| Lymphocyte Count Decreased |
3.6% |
| Thrombocytopenia |
3.3% |
| Ileus |
3.0% |
| Neutrophil Count Decreased |
3.0% |
| Hypoacusis |
2.8% |
| Pneumonia |
2.5% |
| Bone Marrow Failure |
1.9% |
| Urticaria |
1.9% |
| Wound Infection |
1.9% |
| Goitre |
1.8% |
| Disease Progression |
1.6% |
| Platelet Count Decreased |
1.5% |
| Toxic Epidermal Necrolysis |
1.5% |
|
| Concomitant |
| Glioblastoma |
33.5% |
| Epilepsy |
9.4% |
| Premedication |
6.8% |
| Convulsion |
6.1% |
| Drug Use For Unknown Indication |
6.1% |
| Simple Partial Seizures |
5.2% |
| Hypertension |
4.8% |
| Metastatic Malignant Melanoma |
4.8% |
| Malignant Glioma |
3.2% |
| Product Used For Unknown Indication |
3.2% |
| Malignant Melanoma |
2.6% |
| Oligodendroglioma |
1.9% |
| Prophylaxis Of Nausea And Vomiting |
1.9% |
| Antifungal Prophylaxis |
1.6% |
| Glioblastoma Multiforme |
1.6% |
| Hypothyroidism |
1.6% |
| Metastases To Central Nervous System |
1.6% |
| Agitation |
1.3% |
| Brain Neoplasm |
1.3% |
| Brain Stem Glioma |
1.3% |
|
| Malaise |
11.8% |
| Death |
6.6% |
| Epilepsy |
6.6% |
| Abdominal Pain Upper |
5.3% |
| Convulsion |
5.3% |
| Disease Progression |
5.3% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
5.3% |
| Pancreatic Disorder |
5.3% |
| Somnolence |
5.3% |
| Thrombocytopenia |
5.3% |
| Vomiting |
5.3% |
| Constipation |
3.9% |
| Malignant Neoplasm Progression |
3.9% |
| Neoplasm |
3.9% |
| Pancytopenia |
3.9% |
| Renal Failure Acute |
3.9% |
| Stevens-johnson Syndrome |
3.9% |
| Visual Acuity Reduced |
3.9% |
| Balance Disorder |
2.6% |
| Brain Neoplasm Malignant |
2.6% |
|
| Interacting |
| Glioblastoma |
36.4% |
| Pharyngitis |
36.4% |
| Glioblastoma Multiforme |
18.2% |
| Epilepsy |
9.1% |
|
| Thrombocytopenia |
66.7% |
| Toxic Epidermal Necrolysis |
33.3% |
|
